Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

Diabetes

Volumn 49, Issue 12, 2000, Pages 2142-2148

  Lepore, Mauro ^a   Pampanelli, Simone ^a   Fanelli, Carmine ^a   Porcellati, Francesca ^a   Bartocci, Linda ^a   Vincenzo, Antonio Di ^a   Cordoni, Cristina ^a   Costa, Emanuela ^a   Brunetti, Paolo ^a   Bolli, Geremia B ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLARGINE; GLUCOSE; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033661254     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.12.2142     Document Type: Article

References (32)

1. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Control of blood sugar in insulin-dependent diabetes: Comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional therapy
4. Long-term intensive insulin therapy: Effects of HbA(1c), risk for severe and mild hypoglycaemia, status of counterregulation and unawareness of hypoglycaemia
5. Intensified insulin therapy and the risk of severe hypoglycaemia
6. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus
7. Insulin pharmacokinetics
8. Insulin analogues and their potential in the management of diabetes mellitus
9. Use of the short-acting insulin analogue lispro in intensive treatment of IDDM: Importance of appropriate replacement of basal insulin and time-interval injection-meal
10. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime
11. The pharmacokinetic basis of insulin therapy in diabetes mellitus
12. Wirkungsprofil von humanem ultralente-insulin im vergleich mit humanem NPH-insulin
13. Diagnosis and management of diabetic autonomic neuropathy
14. Effects of arterial versus venous sampling on analysis of glucose kinetics in man
15. Studies on overnight insulin requirements and metabolic clearance rate of insulin in normal and diabetic man: Relevance to the pathogenesis of the dawn phenomenon
16. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens
17. Manual feedback technique for the control of blood glucose concentration
18. How to ameliorate the problem of hypoglycemia in intensive as well as non-intensive treatment of type 1 diabetes mellitus
19. Improved post-prandial metabolic control after subcutaneous injection of a short-acting insulin analogue in IDDM of short duration with residual pancreatic β-cell function
20. Contribution of postprandial versus interprandial blood glucose to HbA(1c) in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime
21. Determination of free and total insulin and C-peptide in insulin treated diabetics
22. Nocturnal blood glucose control in type 1 diabetes mellitus
23. Nocturnal hypoglycaemia in patients receiving conventional treatment with insulin
24. Prevention of nocturnal hypoglycemia in intensive therapy of IDDM
25. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycemic clamp technique
26. [Lys(B28),Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin
27. Action profile of the rapid acting insulin analogue human insulin B28Asp
28. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304
29. Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycemic clamp technique
30. Time-action profile of the long-acting insulin analog glargine (HOE901) in comparison with those of NPH insulin and placebo
31. Glucose counterregulation during prolonged hypoglycemia in normal humans